Methsuximide
Anti-epileptic Agent — NERVOUS SYSTEM
Also known as: (+/-)-Mesuximide, celontin, mesuximid, mesuximide, mesuximidum, methsuximid, racemic methsuximide
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Methsuximide is an ofp drug in the Anti-epileptic Agent class catalogued in DrugCentral. It was first approved by the FDA in 1957. DrugCentral lists 1 molecular target, including CACNA1G|CACNA1H|CACNA1I. Recorded indications include Absence seizure and Epilepsy.
- Approval status: ofp (first approved 1957 by the FDA).
- Drug class: Anti-epileptic Agent.
- Molecular targets: CACNA1G|CACNA1H|CACNA1I (1 listed in DrugCentral).
- Indications: Absence seizure and Epilepsy.
- ATC code: N03AD03 (Succinimide derivatives).
- Molecular formula: C12H13NO2; molecular weight 203.24 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Absence seizure
- Epilepsy
Off-label uses (1)
- Epilepsy characterized by intractable complex partial seizures
Contraindications (8)
- Acute intermittent porphyria
- Aggressive behavior
- Depressive disorder
- Disease of liver
- Kidney disease
- Neutropenic disorder
- Suicidal thoughts
- Systemic lupus erythematosus
Mechanism & targets
| Established pharmacologic class | Anti-epileptic Agent |
|---|
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Voltage-gated T-type calcium channel | CACNA1G|CACNA1H|CACNA1I | blocker | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1957-02-08 | FDA | — | PARKE DAVIS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N03AD03 | NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Succinimide derivatives |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Methsuximide is on its molecule page.
| Molecular formula | C12H13NO2 |
|---|---|
| Molecular weight | 203.24 g/mol |
| CAS number | 77-41-8 |
| InChIKey | AJXPJJZHWIXJCJ-UHFFFAOYSA-N |
| PubChem CID | 6476 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Methsuximide used for?
DrugCentral lists the following indications for Methsuximide: Absence seizure and Epilepsy.
How does Methsuximide work?
Its molecular targets in DrugCentral include CACNA1G|CACNA1H|CACNA1I (blocker).
When was Methsuximide first approved?
Methsuximide was first approved by the FDA in 1957.
What drug class does Methsuximide belong to?
Methsuximide is in the Anti-epileptic Agent class.
What is the chemical formula of Methsuximide?
Methsuximide has the molecular formula C12H13NO2 and a molecular weight of 203.24 g/mol.
Browse: all drugs starting with M · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1758 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL697 — compound record and bioactivity
- PubChem CID 6476 — chemical identifiers
- DrugBank DB05246 — drug record
- FDA UNII 0G76K8X6C0 — substance identity
- DailyMed: FDA labels for Methsuximide — current prescribing information (label search)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.